Advertisement

FDA Approves Migraine Prevention Device — Physician’s First Watch

Medical News |
March 12, 2014

FDA Approves Migraine Prevention Device

By Kelly Young

The FDA has approved marketing of the first device to prevent migraine headaches. The Cefaly transcutaneous electrical nerve stimulation (TENS) device is intended to be used, once a day for 20 minutes, by adults with migraines.

The user applies a self-adhesive electrode in the center of the forehead. The device uses an electrical current to stimulate branches of the trigeminal nerve.

A trial of nearly 70 people found that Cefaly users had fewer days with migraine per month and used less medication to control their migraines, compared with patients using a placebo device.

Reader Comments (2)

Jeri Turkel

how does one get this device? sounds great.

Jay Davis MD Physician, Humboldt State University

What a godsend! Perhaps it will be a game-changer as Imitrex was back in the day...

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement